Ho, ho, ho! Gather around, my dear friends, for I have a tale to tell, not of elves and reindeer, but of a rather tricky villain in the land of medicine, known as esophageal squamous cell carcinoma (ESCC). Now, ESCC is a bit like the Grinch of cancers, not often seen but quite troublesome when it does appear, lurking around with a low incidence rate and mortality, but causing a stir in the lives it touches.

In our story, there’s a magical process called the post-translational modification of small ubiquitin-like modifiers (SUMO), which is akin to how I, Santa, make toys function with a bit of Christmas magic. This SUMO magic can significantly impact the occurrence and development of diseases, much like how a sprinkle of elf dust can make a toy come to life.

Enter the heroes of our tale, the SUMO-specific peptidases (SENPs), with SENP3 being a particularly notable character. SENP3, a member of the SENP family, is like one of my most skilled elves, affecting cell activity by regulating the biological function of SUMO. However, the role of SENP3 in the ESCC saga was as mysterious as the Northern Lights until now.

Our story unfolds with the discovery that SENP3 is found in high levels in the villainous ESCC tumor cells. Imagine, if you will, SENP3 as a mischievous elf, whose high presence in ESCC cell lines can significantly impact their naughty activities, such as the invasion of KYSE170 cells, much like how a group of elves might sneak into a kitchen to steal cookies. But, if this mischievous elf, SENP3, is knocked out, the cookies—ahem, the cells—remain untouched.

Further into our tale, we find that SENP3 can effectively activate related signaling pathways, much like how I activate my sleigh with a “Ho, ho, ho!” thereby promoting the physiological activities of these malignant tumor cells. In a magical experiment involving a nude mouse xenograft tumor model, akin to my test flights before Christmas Eve, KYSE170 cells with SENP3 expression knockdown resulted in a smaller volume and weight of tumor tissue, showing that without SENP3’s influence, the tumor’s growth is much like a Christmas without snow—significantly less impactful.

Thus, our story concludes with the revelation that SENP3 can enable the Wnt/β-catenin signaling pathway, affecting the physiological activities of ESCC cells, including their invasion process. This tale lays the foundation for the clinical staff, much like my elves, to carry out clinical management, bringing hope to those affected by ESCC, much like how I bring joy on Christmas morning.

And so, my dear friends, as we close this chapter, let us remember the importance of understanding and combating the Grinches of the medical world, with the hope of a healthier tomorrow. Merry Christmas to all, and to all a good night!